Population pharmacokinetic-pharmacodynamic (PK-PD) modeling of CPX-351-induced thrombocytopenia

被引：0
|
作者：
Cook, Sarah F. [1 ]
Wang, Qi [2 ]
Mager, Donald E. [1 ]
Van Wart, Scott A. [1 ]
机构：
[1] Enhanced Pharmacodynam LLC, Buffalo, NY USA
[2] Jazz Pharmaceut Inc, Palo Alto, CA USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-025
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [41] The pharmacokinetic-pharmacodynamic (PK-PD) relationship of pasireotide (SOM230), a novel somatostatin analogue, in patients with acromegaly.
    Lee, Lucy
    Glusman, J.
    Gao, B.
    Buchelt, A.
    Deckert, F.
    Schran, H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1086 - 1086
  • [42] Population Pharmacokinetic-Pharmacodynamic Modeling of Neutrophil and Platelet Count for Lower-Intensity Therapy of CPX-351 Combined with Venetoclax in Acute Myeloid Leukemia
    Liang, Yali
    Cook, Sarah F.
    Cheung, Ronald
    Zhou, Honghui
    Coppola, Sheryl
    Wang, Qi
    Mager, Donald E.
    Van Wart, Scott A.
    BLOOD, 2023, 142
  • [43] Pharmacokinetic-pharmacodynamic (PK-PD) correlation of ibuprofen analgesia: Comparison between ibuprofen arginate (IA) and motrin IB (MO).
    Arends, R
    Shen, D
    Desjardins, P
    Max, M
    Norwood, T
    McAuley, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII20 - PII20
  • [44] Effect of pharmacodynamic baseline changes in linked & indirect pharmacokinetic pharmacodynamic (pk-pd) models.
    Young, D
    Piscitelli, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI103 - PI103
  • [45] A Pharmacokinetic-Pharmacodynamic (PK-PD)-Based Treatment Strategy With Ceftriaxone (CTRX) for Acute Cholangitis That Was Proven to Be Effective in Actual Clinical Practice
    Toki, Masao
    Yamaguchi, Yasuharu
    Nakamura, Kenji
    Takahashi, Shin'ichi
    GASTROENTEROLOGY, 2011, 140 (05) : S448 - S449
  • [46] Effect of reslizumab exposure on efficacy outcomes in a pharmacokinetic-pharmacodynamic (PK-PD) analysis of weight-based intravenous (IV) dosing
    Passarell, Julie
    Jaworowicz, David
    Fiedler-Kelly, Jill
    Ludwig, Elizabeth
    Marsteller, Douglas A.
    Garin, Margaret
    Rabinovich-Guilatt, Laura
    ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (05) : 359 - 359
  • [47] POPULATION PHARMACOKINETIC (PK) AND PHARMACOKINETIC-PHARMACODYNAMIC (PK/PD) ASSESSMENT OF GDC-0334 (A TRPA1 INHIBITOR) IN HEALTHY SUBJECTS.
    Chan, H.
    Li, H.
    Liu, L.
    Ding, H.
    Ferl, G.
    Bauer, R.
    Gao, S.
    Joseph, V.
    Yang, X.
    Quartino, A.
    Putnam, W.
    Pan, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S98 - S98
  • [48] Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia
    Zoubir Djerada
    Catherine Feliu
    Yoann Cazaubon
    Faouzi Smati
    Philippe Gomis
    Dominique Guerrot
    Beny Charbit
    Olivier Fernandes
    Jean-Marc Malinovsky
    Clinical Pharmacokinetics, 2018, 57 : 1135 - 1147
  • [49] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING OF 5-FLUOROURACIL (5-FU) USING HEPATIC DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) ACTIVITY LEVELS FOR MYELOSUPPRESSION IN RATS
    Kobuchi, Shinji
    Ito, Yukako
    Hayakawa, Taro
    Nishimura, Asako
    Shibata, Nobuhito
    Sakaeda, Toshiyuki
    DRUG METABOLISM REVIEWS, 2015, 47 : 234 - 235
  • [50] Population pharmacokinetic-pharmacodynamic modeling of spinal anesthesia with ropivacaine
    Djerada, Z.
    Feliu, C.
    Cazaubon, Y.
    Smati, F.
    Gomis, P.
    Charbit, B.
    Fernandes, O.
    Malinovsky, J. M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 18 - 18
12345